PMID- 7691405
OWN - NLM
STAT- MEDLINE
DCOM- 19931123
LR  - 20041117
IS  - 0361-090X (Print)
IS  - 0361-090X (Linking)
VI  - 17
IP  - 3
DP  - 1993
TI  - Cancer-associated SCM-recognition, immunedefense suppression, and serine protease 
      protection peptide. Part II. Immunedefense suppressive effects of the CRISPPs 
      peptide.
PG  - 433-45
AB  - The cancer SCM-recognition, immunedefense suppression, and serine protease 
      protection (CRISPP) peptide, a product of a hereditary or acquired heritable 
      alpha 1-PI gene DNA mutation in cancer cells, is a potent suppressor of the 
      natural killer (NK) and lymphokine activated killer (LAK) cytotoxicity against 
      cancer cells. The "NK suppression epitope" encompasses amino acid residues 8 to 
      29 of the 29 amino acid sequence of the CRISPPs peptide. The NK suppression is 
      peptide dose and incubation time dependent. The formation of conjugates between 
      effector and target cells is not affected by the peptide, but the release of 
      interleukin-2 (IL-2) and of tumor necrosis factor-alpha (TNF alpha) from 
      lymphocytes is significantly decreased after treatment of lymphocytes with the 
      CRISPPs peptide. The suppression of NK and LAK activity of lymphocytes by the 
      CRISPPs peptide cannot be removed by washing, nor can it be reversed by 
      subsequent treatment with recombinant interleukin-2 (rIL-2). However, autologous 
      cell-free blood plasma, especially plasma ultrafiltrates of molecular weights 
      higher than 100 kDa, can restore up to 83% of the NK activity. Scavenging of the 
      CRISPPs peptide with anti-CRISPPs antibodies prevents the suppression of NK 
      cytotoxicity. The relevance of CRISPP peptides for adoptive immunotherapy is 
      discussed.
FAU - Cercek, L
AU  - Cercek L
AD  - Beckman Instruments Inc., Diagnostic Systems Group, Brea, CA 92621.
FAU - Cercek, B
AU  - Cercek B
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cancer Detect Prev
JT  - Cancer detection and prevention
JID - 7704778
RN  - 0 (Epitopes)
RN  - 0 (Interleukin-2)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (cancer-recognition, immunedefense suppression, serine protease protection 
      peptide)
SB  - IM
MH  - Cytotoxicity, Immunologic/*drug effects
MH  - Dose-Response Relationship, Immunologic
MH  - Epitopes/*isolation & purification
MH  - Humans
MH  - Interleukin-2/metabolism
MH  - Killer Cells, Lymphokine-Activated/drug effects/*immunology
MH  - Killer Cells, Natural/drug effects/*immunology
MH  - Neoplasm Proteins/*pharmacology
MH  - Time Factors
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factor-alpha/drug effects/metabolism
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Cancer Detect Prev. 1993;17(3):433-45.